Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation

NCT01967888 is registered in ClinicalTrials.gov with Dompé Farmaceutici S.p.A as lead sponsor.

NCT NCT01967888
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01967888 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Assignment Study to Assess the Efficacy and Safety of Reparixin in Pancreatic Islet Auto-transplantation
Lead sponsor
Dompé Farmaceutici S.p.A
Phase
Phase 2/3
Overall status
Completed
Start date
February 28, 2014
Completion date
January 31, 2018
Enrollment
104 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatectomy for chronic pancreatitis